Positive News SentimentPositive NewsNASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free OPRX Stock Alerts $11.00 -0.12 (-1.08%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$10.86▼$11.2850-Day Range$8.80▼$13.1752-Week Range$6.92▼$16.65Volume85,881 shsAverage Volume115,989 shsMarket Capitalization$200.97 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get OptimizeRx alerts: Email Address OptimizeRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside45.5% Upside$16.00 Price TargetShort InterestBearish6.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.74Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.42) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.59 out of 5 starsComputer And Technology Sector467th out of 587 stocksBusiness Services, Not Elsewhere Classified Industry79th out of 93 stocks 3.4 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOptimizeRx has only been the subject of 3 research reports in the past 90 days.Read more about OptimizeRx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.44% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in OptimizeRx has recently increased by 12.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 3.2 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OptimizeRx this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.42) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About OptimizeRx Stock (NASDAQ:OPRX)OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.Read More OPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Stock News HeadlinesMay 15, 2024 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Reports First Quarter 2024 Financial ResultsMay 15, 2024 | marketwatch.comOptimizeRx Shares Rise 23% on 1Q Revenue Beat, FY GuidanceMay 15, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)May 15, 2024 | msn.comOptimizeRx Corporation (NASDAQ:OPRX) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comOptimizeRx Corp (OPRX) Q1 2024 Earnings Call Transcript Highlights: Surging Revenues and ...May 14, 2024 | investorplace.comOPRX Stock Earnings: OptimizeRx Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | globenewswire.comOptimizeRx Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comOptimizeRx to Participate in Upcoming Investor ConferencesApril 29, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for AbbVie: Future Growth Beyond Humira’s CompetitionApril 26, 2024 | globenewswire.comOptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ETApril 18, 2024 | globenewswire.comOptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) ReportApril 16, 2024 | globenewswire.comOptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsApril 13, 2024 | stockhouse.comOptimizeRx Named America's Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | finance.yahoo.comOptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | finance.yahoo.comOptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | globenewswire.comOptimizeRx Named America's Fastest-Growing Company for Fifth Year in a RowApril 6, 2024 | investorplace.com7 Top Undervalued Stocks Primed for a Multibagger RecoveryApril 4, 2024 | markets.businessinsider.comOptimizeRx: A Strong Buy on Strategic Acquisitions and Innovative Platform ExpansionApril 2, 2024 | au.lifestyle.yahoo.comTesla blames sales drop on Houthi attacks and arson in GermanyApril 1, 2024 | msn.comAriana Madix To Host ‘Love Island USA’ as Sarah Hyland Departs FranchiseApril 1, 2024 | au.news.yahoo.comCanoo spent double its annual revenue on the CEO’s private jet in 2023April 1, 2024 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 OPTIMIZERx Corp Earnings CallMarch 28, 2024 | investorplace.comOPRX Stock Earnings: OptimizeRx Beats Revenue for Q4 2023March 28, 2024 | msn.comOptimizeRx Q4 revenue $28.4MSee More Headlines Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees135Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+45.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-23.10% Pretax Margin-32.38% Return on Equity-6.96% Return on Assets-5.53% Debt Debt-to-Equity Ratio0.26 Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual Sales$71.52 million Price / Sales2.81 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book1.58Miscellaneous Outstanding Shares18,270,000Free Float17,466,000Market Cap$200.97 million OptionableOptionable Beta1.28 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. William J. Febbo (Age 55)CEO & Director Comp: $863.15kMr. Stephen L. Silvestro (Age 46)President Comp: $591.62kMr. Edward Stelmakh C.M.A. (Age 58)M.B.A., CFO & COO Comp: $626.74kMr. Andrew Jacob D'SilvaSenior Vice President of Corporate FinanceKey CompetitorsLimelight NetworksNASDAQ:LLNWRadwareNASDAQ:RDWRViadNYSE:VVIOLONYSE:OLOInternational Money ExpressNASDAQ:IMXIView All CompetitorsInsiders & InstitutionsAWM Investment Company Inc.Bought 33,000 shares on 5/16/2024Ownership: 4.692%Kennedy Capital Management LLCSold 170,886 shares on 5/16/2024Ownership: 1.759%First Light Asset Management LLCBought 10,286 shares on 5/15/2024Ownership: 9.558%Hillsdale Investment Management Inc.Sold 5,000 shares on 5/11/2024Ownership: 0.059%Vanguard Group Inc.Bought 6,291 shares on 5/10/2024Ownership: 5.649%View All Insider TransactionsView All Institutional Transactions OPRX Stock Analysis - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price target for 2024? 7 equities research analysts have issued 1-year price objectives for OptimizeRx's shares. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2024? OptimizeRx's stock was trading at $14.31 at the beginning of the year. Since then, OPRX shares have decreased by 23.1% and is now trading at $11.00. View the best growth stocks for 2024 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Tuesday, May, 14th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.16. The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $18.66 million. OptimizeRx had a negative trailing twelve-month return on equity of 6.96% and a negative net margin of 23.10%. During the same period in the previous year, the company earned ($0.34) EPS. What ETF holds OptimizeRx's stock? Jacob Forward ETF holds 10,785 shares of OPRX stock, representing 4.52% of its portfolio. What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $104.7 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by a number of retail and institutional investors. Top institutional investors include First Light Asset Management LLC (9.56%), Vanguard Group Inc. (5.65%), AWM Investment Company Inc. (4.69%), Blair William & Co. IL (4.30%), Rice Hall James & Associates LLC (2.21%) and Kennedy Capital Management LLC (1.76%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPRX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.